newsfilter
← Latest News
GlobeNewswire·

Liquidia Corporation Reports Third Quarter 2026 Financial Results

LQDA
  • Liquidia reported YUTREPIA net product sales of $222.7 million in Q3 2026, a 31% increase from Q2 2026.
  • October 2026 total patient shipments reached their highest monthly level since launch.
  • Liquidia resolved all litigation with United Therapeutics via a global settlement, securing continuity of care for YUTREPIA patients.
  • The company recorded a net loss of $236.3 million for Q3 2026, reflecting a $389.7 million litigation settlement charge.
  • Liquidia achieved its fifth consecutive quarter of increasing non-GAAP adjusted EBITDA, reaching $140.5 million in Q3 2026.
  • Cash & cash equivalents totaled $396.1 million prior to settlement payments.
  • FDA granted Fast Track designation for YUTREPIA for SSc-RP treatment, with initiation of the Phase 2 RE-WARM study.
  • Liquidia initiated LTI-403, SPRINT, EASY-PAH, and RE-WARM clinical studies while advancing L606 trials for PH-ILD, PAH, and PH-COPD.
  • Under the settlement, Liquidia agreed to pay net $380.7 million in installments over 2026-2027.
  • Liquidia submitted a Prior Approval Supplement to remove the PH-ILD indication from the YUTREPIA label.
  • Service revenue from the Sandoz promotion agreement ended in October 2026, with no future service revenue expected.
  • R&D expenses increased to $25.3 million in Q3 2026, driven primarily by the L606 program.
  • Selling, general, administrative expenses rose to $59.0 million in Q3 2026 due to higher headcount, stock-based compensation, commercial costs.
  • The prescriber base reached 1,300 by October 2026, with over 77% writing PAH prescriptions since launch.
Company
Liquidia Technologies, Inc.
Keywords
Nasdaq:LQDA, Liquidia Technologies, Inc.